IP Library › Granted Patent US 12,365,658
Granted Patent B2
US 12,365,658 · App. 17/813,152 · Granted Jul 22, 2025

Benzothia(di)azepine compounds and their use as bile acid modulators

Inventors: Per-Göran Gillberg (Åsbro, SE); Ingemar Starke (Gothenburg, SE); Santosh S. Kulkarni (Bangalore, IN)
Assignee: ALBIREO AB
C07D281/10C07D285/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,658
App. No.
17/813,152
Granted
Jul 22, 2025
Kind
B2
Abstract

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Claims (76)

1. A compound of formula (I)

wherein

M is selected from —CH 2 — and —NR 5 —;

R 1 is C 1-4 alkyl;

R 2 is independently selected from the group consisting of hydrogen, halogen, hydroxy, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, cyano, nitro, amino, N—(C 1-4 alkyl)amino, N,N-di(C 1-4 alkyl)amino, C 1-6 alkylcarbonylamino, C 3-6 cycloalkylcarbonylamino, N—(C 1-4 alkyl)aminocarbonyl, N,N-di(C 1-4 alkyl)aminocarbonyl, C 1-4 alkyloxycarbonylamino, C 3-6 cycloalkyloxycarbonylamino, C 1-4 alkylsulfonamido and C 3-6 cycloalkylsulfonamido;

n is an integer 1, 2 or 3;

R 3 is selected from the group consisting of hydrogen, halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, C 1-4 alkoxy, C 3-6 cycloalkyloxy, C 1-4 alkylthio, C 3-6 cycloalkylthio, amino, N—(C 1-4 alkyl)amino and N,N-di(C 1-4 alkyl)amino;

R 4A and R 4B are each independently selected from the group consisting of hydrogen, halogen, hydroxy, C 1-4 alkyl and C 1-4 alkoxy; or R 4A and R 4B , together with the carbon atom to which they are attached, form a 3- to 5-membered saturated carbocyclic ring;

R 4C and R 4D are each independently selected from the group consisting of hydrogen and C 1-4 alkyl; and

R 5 is selected from the group consisting of hydrogen and C 1-4 alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein R 1 is C 2-4 alkyl.

3. The compound according to claim 1 , wherein R 1 is n-propyl or n-butyl.

4. The compound according to 1 , wherein R 2 is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, methoxy, amino, methylamino and dimethylamino.

5. The compound according to 1 , wherein R 3 is selected from the group consisting of fluoro, chloro, bromo, methyl, cyclopropyl, methoxy, ethoxy, methylthio, ethylthio, amino, methylamino and dimethylamino.

6. The compound according to claim 1 , wherein R 4A and R 4B are each independently selected from the group consisting of hydrogen, halogen, hydroxy, C 1-4 alkyl and C 1-4 alkoxy, or R 4A and R 4B , together with the carbon atom to which they are attached, form a cyclopropyl ring.

7. The compound according to claim 1 , wherein R 4C and R 4D are each independently hydrogen or methyl.

8. The compound according to claim 1 , wherein R 5 is hydrogen or methyl.

9. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yloxy-2,2-dimethylpropanoic acid;

(S)-3-(3-butyl-2-methyl-7-(methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yloxy-22-dimethylpropanoic acid;

(R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid;

1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

(S)-1-(((3-butyl-2-methyl-7-(methylthio-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

(R)-1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid;

(S)-3-((3-butyl 7-(ethylthio)-2-methyl-1,1 dioxido-5-phenyl-2,3,1,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid;

(R)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid;

1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

(S)-1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

(R)-1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid;

1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

(S)-1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

(R)-1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid;

(S)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid;

(R)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid;

1-(((3-butyl-7-(ethylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

(S)-1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

(R)-1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

(S)-1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

(R)-1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid;

3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-difluoropropanoic acid;

(S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-difluoropropanoic acid;

(R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-difluoropropanoic acid;

3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2334,45-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxy-2-methylpropanoic acid;

(S)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxy-2-methylpropanoic acid;

(S)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxy-2-methylpropanoic acid;

(R)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxy-2-methylpropanoic acid;

(R)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxy-2-methylpropanoic acid;

3-((3-butyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)propanoic acid;

(S)-3-((3-butyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)propanoic acid;

(R)-3-((3-butyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)propanoic acid;

3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-ethoxypropanoic acid;

3-((3-butyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)-2-hydroxypropanoic acid;

3-((3-ethyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl)oxy)propanoic acid;

3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxypropanoic acid;

3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxypropanoic acid;

3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxypropanoic acid;

(S)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxypropanoic acid;

(R)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxypropanoic acid;

(S)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxypropanoic acid;

(R)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxypropanoic acid; and

3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxido-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-hydroxypropanoic acid;

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 9 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

12. A method for treating a disease or disorder comprising orally administering to a subject in need of such treatment a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is selected from the group consisting of: a cardiovascular disease; a disorder of fatty acid metabolism; a glucose utilization disorder; a gastrointestinal disease or disorder; a hyperabsorption syndrome; hypervitaminosis and osteopetrosis; hypertension; glomerular hyperfiltration; polycystic kidney disease (PKD); and pruritus of renal failure.

13. The method of claim 12 , wherein the cardiovascular disease, disorder of fatty acid metabolism, or glucose utilization disorder is selected from the group consisting of: hypercholesterolemia; type 1 or type 2 diabetes mellitus; complications of diabetes; insulin resistance; hyperglycemia; hyperinsulinemia; elevated blood levels of fatty acids or glycerol; obesity; dyslipidemia; and hyperlipidemia.

14. The method of claim 12 , wherein the gastrointestinal disease or disorder is selected from the group consisting of: constipation; Crohn's disease; primary bile acid malabsorption; irritable bowel syndrome (IBS); inflammatory bowel disease (IBD); ileal inflammation; and reflux disease and complications thereof.

15. A method for treating a liver disease or disorder comprising orally administering to a subject in need of such treatment a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , wherein the liver disease or disorder is selected from the group consisting of: inherited metabolic disorder of the liver; an inborn error of bile acid synthesis; a congenital bile duct anomaly; biliary atresia; post-Kasai biliary atresia; post-liver transplantation biliary atresia; neonatal hepatitis; neonatal cholestasis; hereditary forms of cholestasis; cerebrotendinous xanthomatosis; a secondary defect of BA synthesis; Zellweger's syndrome; cystic fibrosis-associated liver disease; alpha1-antitrypsin deficiency; Alagilles syndrome (ALGS); Byler syndrome; a primary defect of bile acid (BA) synthesis; progressive familial intrahepatic cholestasis (PFIC); benign recurrent intrahepatic cholestasis (BRIC); autoimmune hepatitis; primary biliary cirrhosis (PBC); liver fibrosis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); portal hypertension; cholestasis; Down syndrome cholestasis; drug-induced cholestasis; intrahepatic cholestasis of pregnancy (jaundice during pregnancy); intrahepatic cholestasis; extrahepatic cholestasis; parenteral nutrition associated cholestasis (PNAC); low phospholipid-associated cholestasis; lymphedema cholestasis syndrome 1 (LCS1); primary sclerosing cholangitis (PSC); immunoglobulin G4 associated cholangitis; primary biliary cholangitis; cholelithiasis (gallstones); biliary lithiasis; choledocholithiasis; gallstone pancreatitis; Caroli disease; malignancy of bile ducts; malignancy causing obstruction of the biliary tree; biliary strictures; AIDS cholangiopathy; ischemic cholangiopathy; pruritus due to cholestasis or jaundice; pancreatitis; chronic autoimmune liver disease leading to progressive cholestasis; hepatic steatosis; alcoholic hepatitis; acute fatty liver; fatty liver of pregnancy; drug-induced hepatitis; iron overload disorders; congenital bile acid synthesis defect type 1 (BAS defect type 1); drug-induced liver injury (DILI); hepatic fibrosis; congenital hepatic fibrosis; hepatic cirrhosis; Langerhans cell histiocytosis (LCH); neonatal ichthyosis sclerosing cholangitis (NISCH); erythropoietic protoporphyria (EPP); idiopathic adulthood ductopenia (IAD); idiopathic neonatal hepatitis (INH); non syndromic paucity of interlobular bile ducts (NS PILBD); North American Indian childhood cirrhosis (NAIC); hepatic sarcoidosis; amyloidosis; necrotizing enterocolitis; serum bile acid-caused toxicities; polycystic liver disease; viral hepatitis; hepatocellular carcinoma (hepatoma); cholangiocarcinoma; a bile acid-related gastrointestinal cancer; and cholestasis caused by tumours and neoplasms of the liver, of the biliary tract and of the pancreas.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2023
From: GILLBERG, PER-GÖRAN; STARKE, INGEMAR
To: ALBIREO AB
Reel/Frame 063056/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2023
From: KULKARNI, SANTOSH S.
To: SYNGENE INTERNATIONAL LTD
Reel/Frame 063056/0982 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2023
From: SYNGENE INTERNATIONAL LTD
To: ALBIREO AB
Reel/Frame 063057/0127 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2023
From: GILLBERG, PER-GÖRAN; STARKE, INGEMAR
To: ALBIREO AB
Reel/Frame 063057/0252 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2023
From: KULKARNI, SANTOSH S.
To: SYNGENE INTERNATIONAL LTD
Reel/Frame 063057/0364 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2023
From: SYNGENE INTERNATIONAL LTD
To: ALBIREO AB
Reel/Frame 063057/0463 →
Priority Claims (1)
IN 202111024711 · Jun 3, 2021 · national
Continuity (2)
Continuation PCTEP2022065165 · Jun 3, 2022
Related Publication 20220402885A1 · Dec 22, 2022
References Cited (400)
US 3539380A · Johnson · 1970 [cited by applicant]
US 4507235A · Wunsch · 1985 [cited by applicant]
US 5167965A · Schulz · 1992 [cited by applicant]
US 5384130A · Kamada · 1995 [cited by applicant]
US 5663165A · Brieaddy · 1997 [cited by applicant]
US 5723458A · Brieaddy et al. · 1998 [cited by applicant]
US 5811388A · Friend et al. · 1998 [cited by applicant]
US 5817652A · Brieaddy et al. · 1998 [cited by applicant]
US 5900233A · Day · 1999 [cited by applicant]
US 5910494A · Brieaddy · 1999 [cited by applicant]
US 5976811A · Mullner et al. · 1999 [cited by applicant]
US 5994391A · Lee et al. · 1999 [cited by applicant]
US 5998400A · Brieaddy et al. · 1999 [cited by applicant]
US 6020330A · Enhsen et al. · 2000 [cited by applicant]
US 6069167A · Sokol · 2000 [cited by applicant]
US 6277831B1 · Frick et al. · 2001 [cited by applicant]
US 6346527B1 · Takanaka et al. · 2002 [cited by applicant]
US 6355672B1 · Yasuma et al. · 2002 [cited by applicant]
US 6387924B2 · Lee et al. · 2002 [cited by applicant]
US 6387944B1 · Frick et al. · 2002 [cited by applicant]
US 6426340B1 · Gibson et al. · 2002 [cited by applicant]
US 6562860B1 · Keller et al. · 2003 [cited by applicant]
US 6635280B2 · Shell et al. · 2003 [cited by applicant]
US 6642269B2 · Frick et al. · 2003 [cited by applicant]
US 6676979B2 · Marlett et al. · 2004 [cited by applicant]
US 6784201B2 · Lee et al. · 2004 [cited by applicant]
US 6906058B2 · Starke et al. · 2005 [cited by applicant]
US 6943189B2 · Keller et al. · 2005 [cited by applicant]
US 7019023B2 · Frick et al. · 2006 [cited by applicant]
US 7125864B2 · Starke et al. · 2006 [cited by applicant]
US 7132416B2 · Starke et al. · 2006 [cited by applicant]
US 7132557B2 · Wilkes et al. · 2006 [cited by applicant]
US 7192945B2 · Starke et al. · 2007 [cited by applicant]
US 7192946B2 · Starke et al. · 2007 [cited by applicant]
US 7192947B2 · Starke et al. · 2007 [cited by applicant]
US 7226943B2 · Starke et al. · 2007 [cited by applicant]
US 7238684B2 · Starke et al. · 2007 [cited by applicant]
US 7514421B2 · Abrahamsson et al. · 2009 [cited by applicant]
US 7615536B2 · Frick et al. · 2009 [cited by applicant]
US 7767229B1 · Milne et al. · 2010 [cited by applicant]
US 7923468B2 · Frick et al. · 2011 [cited by applicant]
US 7939061B2 · Prakash et al. · 2011 [cited by applicant]
US 7956085B2 · Frick et al. · 2011 [cited by applicant]
US 8048413B2 · Huguet · 2011 [cited by applicant]
US 8067584B2 · Starke et al. · 2011 [cited by applicant]
US 8101583B2 · Glombik et al. · 2012 [cited by applicant]
US 8106023B2 · Glombik et al. · 2012 [cited by applicant]
US 9295677B2 · Ling et al. · 2016 [cited by applicant]
US 9339480B2 · Young et al. · 2016 [cited by applicant]
US 9409875B2 · Bohlin et al. · 2016 [cited by applicant]
US 9684018B2 · Horanzy · 2017 [cited by applicant]
US 9688720B2 · Gillberg et al. · 2017 [cited by applicant]
US 9694018B1 · Gillberg et al. · 2017 [cited by applicant]
US 9701649B2 · Bohlin et al. · 2017 [cited by applicant]
US 9745276B2 · Bohlin et al. · 2017 [cited by applicant]
US 9872844B2 · Zernel et al. · 2018 [cited by applicant]
US 10000528B2 · Gillberg et al. · 2018 [cited by applicant]
US 10011633B2 · Gillberg et al. · 2018 [cited by applicant]
US 10093697B2 · Gillberg et al. · 2018 [cited by applicant]
US 10183920B2 · Ymen et al. · 2019 [cited by applicant]
US 10221212B2 · Gillberg et al. · 2019 [cited by applicant]
US 10428109B1 · Bhat et al. · 2019 [cited by applicant]
US 10487111B2 · Gillberg et al. · 2019 [cited by applicant]
US 10709755B2 · Ando et al. · 2020 [cited by applicant]
US 10793534B2 · Gillberg · 2020 [cited by applicant]
US 10941127B2 · Gilberg et al. · 2021 [cited by applicant]
US 10975045B2 · Gillberg et al. · 2021 [cited by applicant]
US 10975046B2 · Lundqvist et al. · 2021 [cited by applicant]
US 10981952B2 · Gilberg et al. · 2021 [cited by applicant]
US 10995115B2 · Bhat et al. · 2021 [cited by applicant]
US 11014898B1 · Gillberg et al. · 2021 [cited by applicant]
US 11111224B2 · Gillberg · 2021 [cited by applicant]
US 11180465B2 · Gillberg et al. · 2021 [cited by applicant]
US 11225466B2 · Gillberg et al. · 2022 [cited by applicant]
US 11261212B2 · Gillberg et al. · 2022 [cited by applicant]
US 11267794B2 · Gillberg et al. · 2022 [cited by applicant]
US 11306064B2 · Gillberg et al. · 2022 [cited by applicant]
US 11365182B2 · Lundqvist et al. · 2022 [cited by applicant]
US 11377429B2 · Gillberg et al. · 2022 [cited by applicant]
US 11572350B1 · Gillberg et al. · 2023 [cited by applicant]
US 11583539B2 · Gillberg et al. · 2023 [cited by applicant]
US 11603359B2 · Gillberg et al. · 2023 [cited by applicant]
US 11708340B2 · Gillberg et al. · 2023 [cited by applicant]
US 11732006B2 · Gillberg et al. · 2023 [cited by applicant]
US 11773071B2 · Gillberg et al. · 2023 [cited by applicant]
US 11801226B2 · Byrod et al. · 2023 [cited by applicant]
US 11802115B2 · Byrod et al. · 2023 [cited by applicant]
US 11844822B2 · Ando et al. · 2023 [cited by applicant]
US 11859851B2 · Voysey · 2024 [cited by applicant]
US 11891368B2 · Gillberg et al. · 2024 [cited by applicant]
US 12024495B2 · Gillberg et al. · 2024 [cited by applicant]
US 12060338B2 · Gillberg et al. · 2024 [cited by applicant]
US 12091394B2 · Lundqvist et al. · 2024 [cited by applicant]
US 12134606B2 · Gillberg et al. · 2024 [cited by applicant]
US 12187690B2 · Gillberg et al. · 2025 [cited by applicant]
US 12187812B2 · Gillberg et al. · 2025 [cited by applicant]
US 12202809B2 · Gillberg et al. · 2025 [cited by applicant]
US 20020142054A1 · Marlett et al. · 2002 [cited by applicant]
US 20030125316A1 · Keller et al. · 2003 [cited by applicant]
US 20030143183A1 · Knudsen et al. · 2003 [cited by applicant]
US 20030153541A1 · Dudley et al. · 2003 [cited by applicant]
US 20030166927A1 · Starke et al. · 2003 [cited by applicant]
US 20030199515A1 · Mudipalli et al. · 2003 [cited by applicant]
US 20030215843A1 · Poupon et al. · 2003 [cited by applicant]
US 20040014806A1 · Bhat et al. · 2004 [cited by applicant]
US 20040038862A1 · Goodwin et al. · 2004 [cited by applicant]
US 20040062745A1 · Green et al. · 2004 [cited by applicant]
US 20040067933A1 · Starke et al. · 2004 [cited by applicant]
US 20040077625A1 · Tremont et al. · 2004 [cited by applicant]
US 20040082647A1 · Babiak et al. · 2004 [cited by applicant]
US 20040176438A1 · Tremont et al. · 2004 [cited by applicant]
US 20050009805A1 · Sasahara et al. · 2005 [cited by applicant]
US 20050038009A1 · Starke et al. · 2005 [cited by applicant]
US 20050113362A1 · Lindstedt et al. · 2005 [cited by applicant]
US 20050118326A1 · Anfinsen · 2005 [cited by applicant]
US 20050124557A1 · Lindqvist · 2005 [cited by applicant]
US 20050171204A1 · Lindstedt et al. · 2005 [cited by applicant]
US 20050197376A1 · Kayakiri et al. · 2005 [cited by applicant]
US 20050215882A1 · Chenevert et al. · 2005 [cited by applicant]
US 20050266080A1 · Desai et al. · 2005 [cited by applicant]
US 20050282822A1 · Alstermark et al. · 2005 [cited by applicant]
US 20050287178A1 · Steed · 2005 [cited by applicant]
US 20060083790A1 · Anderberg et al. · 2006 [cited by applicant]
US 20070197522A1 · Edwards et al. · 2007 [cited by applicant]
US 20080207592A1 · Frick et al. · 2008 [cited by applicant]
US 20080300171A1 · Balkan et al. · 2008 [cited by applicant]
US 20090131395A1 · Antonelli et al. · 2009 [cited by applicant]
US 20100130472A1 · Young et al. · 2010 [cited by applicant]
US 20100286122A1 · Belyk · 2010 [cited by applicant]
US 20110003782A1 · Pellicciari · 2011 [cited by applicant]
US 20110152204A1 · Gedulin et al. · 2011 [cited by applicant]
US 20110294767A1 · Gedulin et al. · 2011 [cited by applicant]
US 20120114588A1 · Starke et al. · 2012 [cited by applicant]
US 20120157399A1 · Young et al. · 2012 [cited by applicant]
US 20130029938A1 · Aquino et al. · 2013 [cited by applicant]
US 20130059807A1 · Gedulin et al. · 2013 [cited by applicant]
US 20130108573A1 · Gedulin et al. · 2013 [cited by applicant]
US 20130109671A1 · Gedulin et al. · 2013 [cited by applicant]
US 20130225511A1 · Gillberg et al. · 2013 [cited by applicant]
US 20130236541A1 · Gillberg et al. · 2013 [cited by applicant]
US 20140275090A1 · Gedulin et al. · 2014 [cited by applicant]
US 20150031636A1 · Gillberg et al. · 2015 [cited by applicant]
US 20150031637A1 · Gillberg et al. · 2015 [cited by applicant]
US 20160039777A1 · Bohlin et al. · 2016 [cited by applicant]
US 20160146715A1 · Shim et al. · 2016 [cited by applicant]
US 20160193277A1 · Gillberg et al. · 2016 [cited by applicant]
US 20160194353A1 · Gillberg et al. · 2016 [cited by applicant]
US 20160229822A1 · Bohlin · 2016 [cited by applicant]
US 20160237049A1 · Bohlin · 2016 [cited by applicant]
US 20170143738A1 · Ando et al. · 2017 [cited by applicant]
US 20170143783A1 · Ando et al. · 2017 [cited by applicant]
US 20170182059A1 · Gillberg et al. · 2017 [cited by applicant]
US 20170182115A1 · Gillberg et al. · 2017 [cited by applicant]
US 20170240516A1 · Ymen et al. · 2017 [cited by applicant]
US 20180022776A1 · Gillberg et al. · 2018 [cited by applicant]
US 20180030088A1 · Gillberg et al. · 2018 [cited by applicant]
US 20180030089A1 · Gillberg et al. · 2018 [cited by applicant]
US 20180140219A1 · Yin et al. · 2018 [cited by applicant]
US 20180162904A1 · Gillberg et al. · 2018 [cited by applicant]
US 20180362577A1 · Gillberg et al. · 2018 [cited by applicant]
US 20190177286A1 · Ymen et al. · 2019 [cited by applicant]
US 20190276493A1 · Bhat et al. · 2019 [cited by applicant]
US 20190367467A1 · Gillberg et al. · 2019 [cited by applicant]
US 20200002299A1 · Lundqvist · 2020 [cited by applicant]
US 20200109165A1 · Bhat et al. · 2020 [cited by applicant]
US 20200140484A1 · Gillberg et al. · 2020 [cited by applicant]
US 20200247768A1 · Gillberg et al. · 2020 [cited by applicant]
US 20200247769A1 · Gillberg et al. · 2020 [cited by applicant]
US 20200330545A1 · Gillberg et al. · 2020 [cited by applicant]
US 20200376071A1 · Ando et al. · 2020 [cited by applicant]
US 20210017141A1 · Gillberg et al. · 2021 [cited by applicant]
US 20210024475A1 · Lundqvist · 2021 [cited by applicant]
US 20210147372A1 · Gillberg · 2021 [cited by applicant]
US 20210171479A1 · Gillberg · 2021 [cited by applicant]
US 20210171480A1 · Gillberg · 2021 [cited by applicant]
US 20210171481A1 · Gillberg · 2021 [cited by applicant]
US 20210171482A1 · Gillberg · 2021 [cited by applicant]
US 20210171483A1 · Gillberg · 2021 [cited by applicant]
US 20210177767A1 · Byrod · 2021 [cited by applicant]
US 20210179572A1 · Gillberg · 2021 [cited by applicant]
US 20210236511A1 · Byrod · 2021 [cited by applicant]
US 20210299141A1 · Gillberg · 2021 [cited by applicant]
US 20210340175A1 · Gillberg · 2021 [cited by applicant]
US 20210387956A1 · Gillberg · 2021 [cited by applicant]
US 20220041567A1 · Gillberg et al. · 2022 [cited by applicant]
US 20220041568A1 · Gillberg et al. · 2022 [cited by applicant]
US 20220143043A1 · Gillberg · 2022 [cited by applicant]
US 20220162176A1 · Gillberg · 2022 [cited by applicant]
US 20220281832A1 · Lundqvist et al. · 2022 [cited by applicant]
US 20230049950A1 · Gillberg et al. · 2023 [cited by applicant]
US 20230109432A1 · Gillberg et al. · 2023 [cited by applicant]
US 20230250073A1 · Gillberg et al. · 2023 [cited by applicant]
US 20230302012A1 · Gillberg et al. · 2023 [cited by applicant]
US 20230330176A1 · Gillberg et al. · 2023 [cited by applicant]
US 20230338392A1 · Lindström et al. · 2023 [cited by applicant]
US 20230398125A1 · Lindström et al. · 2023 [cited by applicant]
US 20230406832A1 · Gillberg et al. · 2023 [cited by applicant]
US 20240067617A1 · Starke et al. · 2024 [cited by applicant]
US 20240092748A1 · Byrod et al. · 2024 [cited by applicant]
US 20240109854A1 · Gillberg et al. · 2024 [cited by applicant]
US 20240130976A1 · Byrod et al. · 2024 [cited by applicant]
US 20240173333A1 · Mattsson et al. · 2024 [cited by applicant]
US 20240207286A1 · Lindström et al. · 2024 [cited by applicant]
US 20250019353A1 · Gillberg et al. · 2025 [cited by applicant]
US 20250019354A1 · Lundqvist et al. · 2025 [cited by applicant]
DE 3930168 · 1991 [cited by applicant]
DE 19825804 · 2000 [cited by applicant]
EP 0278464 · 1988 [cited by applicant]
EP 0489423 · 1991 [cited by applicant]
EP 0372542 · 1992 [cited by applicant]
EP 0573848 · 1993 [cited by applicant]
EP 0549967 · 1993 [cited by applicant]
EP 0624593 · 1994 [cited by applicant]
EP 0624594 · 1994 [cited by applicant]
EP 0624595 · 1994 [cited by applicant]
EP 0624596 · 1994 [cited by applicant]
EP 0864582 · 1998 [cited by applicant]
EP 1173205 · 2000 [cited by applicant]
EP 1535913 · 2005 [cited by applicant]
EP 2144599 · 2010 [cited by applicant]
EP 3210977 · 2017 [cited by applicant]
GB 1573487 · 1980 [cited by applicant]
GB 2262888 · 1996 [cited by applicant]
JP 2000513028 · 2000 [cited by applicant]
JP 2013541584 · 2013 [cited by applicant]
JP 2013542953 · 2013 [cited by applicant]
JP H02258719 · 2019 [cited by applicant]
WO WO199103249 · 1991 [cited by applicant]
WO WO199316055 · 1993 [cited by applicant]
WO WO199400111 · 1994 [cited by applicant]
WO WO199418183 · 1994 [cited by applicant]
WO WO199418184 · 1994 [cited by applicant]
WO WO199605188 · 1996 [cited by applicant]
WO WO199608484 · 1996 [cited by applicant]
WO WO199616051 · 1996 [cited by applicant]
WO WO199733882 · 1997 [cited by applicant]
WO WO199803818 · 1998 [cited by applicant]
WO WO199807449 · 1998 [cited by applicant]
WO WO199838182 · 1998 [cited by applicant]
WO WO199840375 · 1998 [cited by applicant]
WO WO199856757 · 1998 [cited by applicant]
WO WO199901149 · 1999 [cited by applicant]
WO WO199932478 · 1999 [cited by applicant]
WO WO199935135 · 1999 [cited by applicant]
WO WO199964409 · 1999 [cited by applicant]
WO WO199964410 · 1999 [cited by applicant]
WO WO2000001687 · 2000 [cited by applicant]
WO WO200038725 · 2000 [cited by applicant]
WO WO200038726 · 2000 [cited by applicant]
WO WO200038727 · 2000 [cited by applicant]
WO WO200038728 · 2000 [cited by applicant]
WO WO200038729 · 2000 [cited by applicant]
WO WO200047568 · 2000 [cited by applicant]
WO WO200061568 · 2000 [cited by applicant]
WO WO200062810 · 2000 [cited by applicant]
WO WO200134570 · 2001 [cited by applicant]
WO WO200160807 · 2001 [cited by applicant]
WO WO200166533 · 2001 [cited by applicant]
WO WO200168096 · 2001 [cited by applicant]
WO WO200168637 · 2001 [cited by applicant]
WO WO200208211 · 2002 [cited by applicant]
WO WO200232428 · 2002 [cited by applicant]
WO WO200250051 · 2002 [cited by applicant]
WO WO200253548 · 2002 [cited by applicant]
WO WO2003020710 · 2003 [cited by applicant]
WO WO2003022286 · 2003 [cited by applicant]
WO WO2003022804 · 2003 [cited by applicant]
WO WO2003022825 · 2003 [cited by applicant]
WO WO2003022830 · 2003 [cited by applicant]
WO WO2003043992 · 2003 [cited by applicant]
WO WO2003051821 · 2003 [cited by applicant]
WO WO2003051822 · 2003 [cited by applicant]
WO WO2003061663 · 2003 [cited by applicant]
WO WO2003091232 · 2003 [cited by applicant]
WO WO2003106482 · 2003 [cited by applicant]
WO WO2004006899 · 2004 [cited by applicant]
WO WO2004020421 · 2004 [cited by applicant]
WO WO2004056748 · 2004 [cited by applicant]
WO WO2004076430 · 2004 [cited by applicant]
WO WO2004089350 · 2004 [cited by applicant]
WO WO2005082874 · 2005 [cited by applicant]
WO WO2007009655 · 2007 [cited by applicant]
WO WO2007009656 · 2007 [cited by applicant]
WO WO2008058628 · 2008 [cited by applicant]
WO WO2008058630 · 2008 [cited by applicant]
WO WO2008058631 · 2008 [cited by applicant]
WO WO2010062861 · 2010 [cited by applicant]
WO WO2010041268 · 2010 [cited by applicant]
WO WO2010106249A1 · 2010 [cited by applicant]
WO WO2011137135 · 2011 [cited by applicant]
WO WO2011150286 · 2011 [cited by applicant]
WO WO2012064266 · 2012 [cited by applicant]
WO WO2012064267 · 2012 [cited by applicant]
WO WO2012064268 · 2012 [cited by applicant]
WO WO2013063512 · 2013 [cited by applicant]
WO WO2013063526 · 2013 [cited by applicant]
WO WO2013168671 · 2013 [cited by applicant]
WO WO2014174066 · 2014 [cited by applicant]
WO WO2016062848 · 2016 [cited by applicant]
WO WO2017138876 · 2017 [cited by applicant]
WO WO2017138877 · 2017 [cited by applicant]
WO WO2017138878 · 2017 [cited by applicant]
WO WO2019017724 · 2019 [cited by applicant]
WO WO2019032026 · 2019 [cited by applicant]
WO WO2019032027 · 2019 [cited by applicant]
WO WO2019172834 · 2019 [cited by applicant]
WO WO2019234077 · 2019 [cited by applicant]
WO WO2019245448 · 2019 [cited by applicant]
WO WO2019245449 · 2019 [cited by applicant]
WO WO2020194531A1 · 2020 [cited by applicant]
WO WO2020161216 · 2020 [cited by applicant]
WO WO2020161217 · 2020 [cited by applicant]
WO WO2020167958 · 2020 [cited by applicant]
WO WO2020167964 · 2020 [cited by applicant]
WO WO2020167981 · 2020 [cited by applicant]
WO WO2020167985 · 2020 [cited by applicant]
WO WO2021110883A1 · 2021 [cited by applicant]
WO WO2021110884 · 2021 [cited by applicant]
WO WO2021110885 · 2021 [cited by applicant]
WO WO2021110886 · 2021 [cited by applicant]
WO WO2021110887 · 2021 [cited by applicant]
WO WO2022029101 · 2022 [cited by applicant]
WO WO2022101379A1 · 2022 [cited by applicant]
WO WO2022117778 · 2022 [cited by applicant]
WO WO2022253997 · 2022 [cited by applicant]
WO WO2023203248A1 · 2023 [cited by applicant]
WO WO2024008766 · 2024 [cited by applicant]
WO WO2024008766A1 · 2024 [cited by applicant]
[No Author Listed], “Practical Pharmaceutical Preparation Technology”, People's Medical Publishing House, Jan. 1999, 286-287 (Machine Translation). [cited by applicant]
A Long-Term, Open-Label Study of LUM001 With a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period to Evaluate Safety and Efficacy in Children With Alagille Syndrome (ICONIC), Clinical Trials.gov, Jun. 9… [cited by applicant]
AASLD: 2017 68th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, Oct. 20-24, 2017, (Abstract only). [cited by applicant]
Adams et al., “Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection,” Clin. Chem. 2005, vol. 51(10), p. 1867-1873. [cited by applicant]
Alagile Syndrome, Wikipedia, the free encyclopedia, posted on or about Feb. 11, 2005, retrieved Feb. 12, 2014, http://en.wikipedia.org/wiki/Alagille syndrome, 3 pages. [cited by applicant]
Alashkar et al., “Meeting Info.: 57th Annual Meeting of the American Society-of-Hematology,” Orlando, FL, USA. Dec. 5-8, 2015, Amer Soc Hematol, Blood, 2015, 126(23). [cited by applicant]
Albireo's Lead Compound in Cholestatic Liver Diseases, A4250, Projects Against Bile Acid-Mediated Cholestatic Liver Injury in Mice, Albireo Press Release, Apr. 11, 2014, 2 pages. [cited by applicant]
Al-Dury, “Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH,” Frontiers in Pharmacology, 2018, 9:931. [cited by applicant]
Alissa et al., “Invited Review: Update on Progressive Familial Intrahepatic Cholestasis,” Journal of Pediatric Gastroenterology and Nutrition, 2008, 46:241-252. [cited by applicant]
Almasio et al., “Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis,” Drugs, 1990, 40 Suppl (3): 111-123. [cited by applicant]
Alonso et al., “Histologic pathology of the liver in progressive familial intrahepatic cholestasis,” Journal of Pediatric Gastroenterology and Nutrition, 14: 128-133, 1994. [cited by applicant]
Alvarez et al., “Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1,” Hum Mol Genet, 2004, 13(20):2451-2460. [cited by applicant]
Alvarez, “Development of crystallization processes for pharmaceutical applications,” LACCEI, 2007, 2E.3-1-2E.3-9. [cited by applicant]
Alvarez, Fernando; “Treatments in chronic cholestasis in children.” Ann. Nestlé (2008) 66 p. 127-135. [cited by applicant]
American Diabetes Association, “Management of Dyslipidemia in Adults with Diabetes,” Diabetes Care, Jan. 2003, 26(1). [cited by applicant]
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (Imagine), ClinicalTrials.gov, Jan. 23, 2014, retri… [cited by applicant]
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (Imagine-II), ClincalTrials.gov, Apr. 16, 2014, ret… [cited by applicant]
Anakk et al., “Bile acids activate YAP to promote liver carcinogenesis,” Cell Rep., Nov. 27, 2013, 5(4):1060-1069. [cited by applicant]
Angulo et al., “Independent Predictors of Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis,” Hepatology, Dec. 1999, 30(6): 1356-1362. [cited by applicant]
Angulo et al., “The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD,” Hepatology, 2007, vol. 45(4), p. 846-54. [cited by applicant]
Angulo, “Use of ursodeoxycholic acid in patients with liver disease,” Current Gastroenterology Reports, Feb. 1, 2002, 4(1):37-44. [cited by applicant]
Anzivino et al., “ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population,” Dig Liver Dis., 2013, 45(3):226-232. [cited by applicant]
Appleby et al., “Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea”, Un… [cited by applicant]
Arnell et al., “Follow-up in children with progressive familial intrahepatic cholestasis after partial external biliary diversion,” J Pediatr Gastroenterol Nutr., 2010, 51(4):494-499. [cited by applicant]
Artursson et al., “Correlation Between Oral Drug Absorption in Humans and Apparent Drug Permeability Coefficients in Human Intestinal Epithelial (CACO-2) Cells,” Biochemical and Biophysical Research Communications, Mar.… [cited by applicant]
Asami et al., “Treatment of children with familial hypercholesterolemia with colestilan, a newly developed bile acid-binding resin,” Atherosclerosis, 2002, 164:381-2. [cited by applicant]
Attili et al., “Bile Acid-induced Liver Toxicity: Relation to the Hydrophobic-Hydrophilic Balance of Bile Acids,” Medical Hypotheses, 1986, 19:57-69. [cited by applicant]
Baghdasaryan et al., “Inhibition of intestinal bile acid absorption by ASBT inhibiton A4250 protects against bile acid-mediated cholestatic liver injury in mice,” J. Hepatology, 2014, 60:S57. [cited by applicant]
Baghdasaryan et al., “Inhibition of intestinal bile acid absorption by ASBT inhibitor A4250 protects against bile acid-mediated cholestatic liver injury in mice,” Presented at the EASL Conference, London, UK, Apr. 12, 2… [cited by applicant]
Bajor et al., “Bile acids: short and long term effects in the intestine,” Scandanavian J. Gastro., 2010, 45:645-664. [cited by applicant]
Baker et al. “Systematic review of progressive familial intrahepatic cholestasis,” Clin Res Hepatol Gastroenterol., 2019;43:20-36. [cited by applicant]
Balbach et al., “Pharmaceutical evaluation of early development candidates “the 100 mg-approach”,” Int J Pharm, May 4, 2004, 275(1):1-12. [cited by applicant]
Banker et al., “Modern Pharmaceutics, 3ed”, Marcel Dekker, New York, 1996, pp. 451 and 596. [cited by applicant]
Baringhaus, “Substrate specificity of the ileal and the hepatic Na+/bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na+/bile acid cotransporter,” J. Lipid Res., 1999, 40:… [cited by applicant]
Baumann, U. et al., “The ileal bile acid transport inhibitor A4250 decreases pruritus and serum bile acids in cholestatic liver diseases—an ongoing multiple dose, open-label, multicenter study,” Hepatology, 2017, 66(1):… [cited by applicant]
Bavin, “Polymorphism in Process Development,” Chemistry and Industry, 527-529, 1989. [cited by applicant]
Beausejour et al., “Description of two new ABCB11 mutations responsible for type 2 benign recurrent intrahepatic cholestasis in a French-Canadian family,” Can J Gastroenterol., 2011, 25(6):311-314. [cited by applicant]
Beraza et al., Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependnt steatohepatitis. Gut, 2011: 60: 387-396. [cited by applicant]
Billington et al., “Effects of bile salts on the plasma membranes of isolated rat hepatocytes,” Bichem. J. 188: 321-327, 1980. [cited by applicant]
Blackmore et al., “Polymorphisms in ABCB11 and ATP8B1 Associated with Development of Severe Intrahepatic Cholestasis in Hodgkin's Lymphoma,” J Clin Exp Hepatol., 2013, 3(2):159-161. [cited by applicant]
Board of Appeal of European Patent Office, Case No. T 077/08-3.3.01, dated May 24, 2011, 17 pages. [cited by applicant]
Boncristani et al., Respiratory Viruses, Encyclopedia of Microbiology, 2009, 19 pages. [cited by applicant]
Bonge et al., “Cytostar-T Scintillating Microplate Assay for Measurement of Sodium-Dependent Bile Acid Uptake in Transfected HEK-293 Cells,” Analytical Biochemistry, 2000, 282:94-101. [cited by applicant]
Bounford. University of Birmingham. Dissertation Abstracts International, (2016) vol. 75, No. IC. Order No. AA110588329. ProQuest Dissertations & Theses. [cited by applicant]
Bowel Diversion Surgeries: Ileostomy, Colostomy, Ileoanal Reservoir and Continent Ileostomy, US Department of Health and Human Services: National Institute of Diabetes and Digestive And Kidney Diseases, Feb. 2009, retri… [cited by applicant]
Brunt et al., “Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging the Histological Lesions,” American Jounral of Gastroenterology, Sep. 1999, 94(9): 2467-2474. [cited by applicant]
Brunzell and Hokanson, “Dislipidemia of Central Obesity and Insulin Resistance,” Diabetes Care, 1999, 22(Suppl. 3):C10-C13. [cited by applicant]
Bull et al., “Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): Evidence for Heterogeneity,” Hepatology, 26: 1, 155-164, 1997. [cited by applicant]
Bull et al., “Progressive Familial Intrahepatic Cholestasis,” Clin Liver Dis., Nov. 2018, 22:4:657-669. [cited by applicant]
Burrows, “Interventions for treating cholestasis in pregnancy,” Cochrane Database Syst. Rev., 4:CD00493, 2001. [cited by applicant]
Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 1995, 12(7), pp. 945-954. [cited by applicant]
Byrne et al., “Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing,” Hepatology., 2009, 49(2):553-567. [cited by applicant]
Caira, “Crystalline Polymorphism of Organic Compounds,” in: Topics in Current Chemistry, Jan. 1998, 198:163-208. [cited by applicant]
Camilleri, “Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy,” Clin. Gastroenterol., 40(3):264-9, Mar. 2006. [cited by applicant]
Centeno, “Molecular mechanisms triggered by low-calcium diets,” Nutrition research reviews., 22(2):163-74, Dec. 2009. [cited by applicant]
Chalasani et al., “The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases,” Hepatology, 2018, 67(1):328-357. [cited by applicant]
Chang et al., “Bile acids promote the expression of hepatitis c virus in replicon-harboring cells,” Journal of Virology, Sep. 2007, 81(18):9633-9640. [cited by applicant]
Chauhan et al., “Pharmaceutical polymers,” Encycl. Biomed. Polymers and Polymeric Biomaterials, 2016, 5929-5942. [cited by applicant]
Chen et al., “Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocelular carcinoma,” Hepatologu, 57: 4, 1530-1541, 2013. [cited by applicant]
Chen et al., “Diagnosis of BSEP/ABCB11 mutations in Asian patients with cholestasis using denaturing high performance liquid chromatography,” J Pediatr., 2008, 153(6):825-832. [cited by applicant]
Chen et al., “FIC1 and BSEP defects in Taiwanese patients with chronic intrahepatic cholestasis with low gamma-glutamyltranspeptidase levels,” Journal of Pediatrics, 2002, 140(1):119-124. [cited by applicant]
Chen et al., “Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes,” Am J Physiol Endocrinol Metab, 2012, 302:E68-E76. [cited by applicant]
Chen et al., “Progressive Familial Intrahepatic Cholestasis, Type 1, Is Associated with Decreased Farnesoid X Receptor Activity,” Gastroenterology, 2004, 126:756-764. [cited by applicant]
Chen et al., “Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma,” Molecular and Cellular Proteomics 10.7, 2011. [cited by applicant]
Chen et al., “The effects of diets enriched in beta-glucans on blood lipoprotein concentrations,” J. Clin. Lipidol., 3(3):154-8, May 2009. [cited by applicant]
Chen et al., “Treatment effect of rifampicin on cholestasis,” Internet Journal of Pharmacology, 4(2), 2006. [cited by applicant]
Chey et al., “A Randomized Placebo-Controlled Phase II b Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation,” Am. J. Gastroenterology, May 2011, 106:1803-1812. [cited by applicant]
Chiang, “Bile acids: regulation of synthesis,” J. Lipid Res, 2009, 50(10):1955-1966. [cited by applicant]
Charach et al., “The association of bile acid excretion and atherosclerotic coronary artery disease,” Therapeutic Advances in Gastroenterology, 2011, 4(2):95-101. [cited by applicant]
Clinical Trials Identifier: NCT03566238, “A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 … [cited by applicant]
Clinical Trials Identifier: NCT03659916, “Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC,” version 11, Oct. 24, 2019, 7 pages. [cited by applicant]
Colorcon.com[online] “Achieving tablet stability with moisture management,” retrieved on May 28, 2021, retrieved from URL<https://www.colorcon.com/connect-with-colorcon/achieving-tablet-stability-with-moisture-managemen… [cited by applicant]
Cited By (1)
US 12,447,156